Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 19/20 | 0.68 |
| ▸ | ITGA4 | P13612 | 19/20 | 0.68 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7102786 | 1.00 | ITGB1 (0.68) | ITGB1ITGA4MEN1ALDH1A1TP53 | |
| SCHEMBL7263425 | 0.85 | ITGB1 (0.63) | ITGB1ITGA4 | |
| SCHEMBL7104117 | 0.85 | ITGB1 (0.71) | ITGB1ITGA4 | |
| SCHEMBL7101237 | 0.84 | ITGB1 (0.82) | ITGB1ITGA4 | |
| SCHEMBL7101244 | 0.84 | ITGB1 (0.82) | ITGB1ITGA4 | |
| SCHEMBL7264590 | 0.84 | ITGB1 (0.70) | ITGB1ITGA4 | |
| SCHEMBL7099962 | 0.83 | ITGB1 (0.72) | ITGB1ITGA4 | |
| SCHEMBL7263184 | 0.83 | ITGB1 (0.72) | ITGB1ITGA4 | |
| SCHEMBL7103814 | 0.83 | ITGB1 (0.61) | ITGB1ITGA4 | |
| SCHEMBL7105903 | 0.82 | ITGB1 (0.65) | ITGB1ITGA4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030162799-A1 | Carbocyclic oxo, carboxy amines such as 3-(4-(3,5-Dichloro-4-pyridylcarboxamido)phenyl)-2-(2-propylamino-3,4 -dioxocyclobut-1-enyl)amino)propanoic acid, used as integrin antagonists; antiinflammatory agents | CELLTECH R&D LIMITED (GB) | 2003-08-28 | — | — | US | disclosed |
| US-6518283-B1 | To modify integrin function in such a way as to beneficially modulate cell adhesion | CELLTECH R&D LIMITED (GB) | 2003-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030162799-A1 | Carbocyclic oxo, carboxy amines such as 3-(4-(3,5-Dichloro-4-pyridylcarboxamido)phenyl)-2-(2-propylamino-3,4 -dioxocyclobut-1-enyl)amino)propanoic acid, used as integrin antagonists; antiinflammatory agents | ICAM1, VCAM1, CCR1 | ITGB1 5/4885ITGA4 28/4885MEN1 4800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.